Comparison of the long‐term and short‐term protection in mouse model of Leishmania major infection following vaccination with Live Iranian Lizard Leishmania mixed with chitin microparticles

Author:

Noroozbeygi Mina1ORCID,Keshavarzian Nafiseh1,Haji Molla Hoseini Mostafa12,Haghdoust Sepideh1,Yeganeh Farshid1ORCID

Affiliation:

1. Department of Immunology School of Medicine, Shahid Beheshti University of Medical Sciences Tehran Iran

2. Medical Nanotechnology and Tissue Engineering Research Center Shahid Beheshti University of Medical Sciences Tehran Iran

Abstract

AbstractInducing long‐term immunity is the primary goal of vaccination. Leishmanisation using non‐pathogenic to human Leishmania spp. could be considered a reliable approach to immunising subjects against Leishmania infection. Here, we evaluated the long‐term immune responses (14 weeks) after immunisation with either live‐ or killed‐Iranian Lizard Leishmania (ILL) mixed with chitin microparticles (CMPs) against L. major infection in BALB/c mice. In total, nine groups of mice were included in the study. To evaluate short‐term immunity, mice were immunised with live‐ILL and CMPs and 3 weeks later were challenged with L. majorEGFP. To evaluate the long‐term immunity, mice were immunised with either live‐ or killed‐ILL both mixed with CMPs, and 14 weeks after immunisation, mice were challenged with L. majorEGFP. A group of healthy mice who received no injection was also included in the study. Eight weeks after the challenge with L. majorEGFP, all subjects were sacrificed and the parasite burden (quantitative real‐time PCR and in vivo imaging), cytokines levels (IFN‐γ, IL‐4 and IL‐10), Leishmania‐specific antibody concentration, and total levels of IgG1 and IgG2a were measured. In addition, nitric oxide concentration and arginase activity were evaluated. Results showed that in mice that were immunised using live‐ILL+CMP, the induced protective immune response lasted at least 14 weeks; since they were challenged with L. majorEGFP at the 14th‐week post‐immunisation, no open lesion was formed during the 8‐week follow‐up, and the footpad swelling was significantly lower than controls. They also showed a significant reduction in the parasite burden in splenocytes, compared to the control groups including the group that received killed‐ILL+CMP. The observed protection was associated with a higher IFN‐γ and a lower IL‐10 production by splenocytes. Additionally, the results demonstrated that arginase activity was decreased in the ILL+CMP group compared to other groups. Immunisation with ILL alone reduced the parasite burden compared to non‐immunised control; however, it was still significantly higher than the parasite burden in the ILL+CMP groups. In conclusion, the long‐term immune response against L. major infection induced by Live‐ILL+CMP was more competent than the response elicited by killed‐ILL+CMP to protect mice against infection with L. majorEGFP.

Funder

School of Medicine, Shahid Beheshti University of Medical Sciences

Publisher

Wiley

Subject

Immunology,Parasitology

Reference58 articles.

1. Leishmaniasis: current challenges and prospects for elimination with special focus on the South Asian region

2. World Health Organization.Status of Endemicity of Cutaneous Leishmaniasis Worldwide 2020. Control of Neglected Tropical Diseases World Health Organization. 2021.

3. Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica Parasites

4. Current approaches to develop a live vaccine against Leishmania major;Yeganeh F;Nov Biomedicine,2017

5. Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3